Skip to main content

Table 2 Treatments and outcomes

From: Role of respiratory intermediate care units during the SARS-CoV-2 pandemic

COVID-19 treatment  
Hydroxychloroquine 73 (69%)
Systemic corticosteroids 66 (62%)
Azithromycin 60 (57%)
Tocilizumab 51 (48%)
Anakinra 22 (21%)
Siltuximab 5 (5%)
Remdesivir 5 (5%)
Respiratory support in RICU  
High flow oxygen nasal cannula 33 (31%)
Non-invasive ventilation 15 (14%)
Days since tracheostomy to decannulation (median [IQR]; n = 31) 25.5 [19–34]
Days since admission to decannulation (median [IQR]; n = 31) 8 [5–12]
NIV duration, days (median [IQR]; n = 14) 4 [1–6.5]
HFNC duration, days (median [IQR]; n = 32) 5 [3–7]
Renal replacement therapy 9 (9%)
Vasopressors 3 (3%)
Destination  
Discharge to COVID-19 ward 75 (71%)
Transfer to ICU 17 (16%)
Death 14 (13%)
Outcomes  
30-day mortality 15 (14%)
Global mortality at 90 days 20 (19%)
Days since admission to RICU (median [IQR]) 13 [4–25.3]
LOS in RICU (median [IQR]) 7 [4–11]
LOS (median [IQR]) 34 [17–52]
Days since admission to death 27 [12–34]
  1. Data is presented as number of patients (%), median [interquartile range]
  2. LOS length of stay (days)